OncoMatch/Clinical Trials/NCT06794775
SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma
Is NCT06794775 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Nivolumab and Nivolumab + Ipilimumab for malignant melanoma stage iii.
Treatment: Nivolumab · Nivolumab + Ipilimumab — At present two studies (SWOG S1801 and NADINA) have demonstrated superiority when using neoadjuvant treatment compared to adjuvant treatment only, but no studies have compared PD-1 monotherapy (SWOG 1801 regimen) to the PD-1/CTLA-4 combination (NADINA regimen) therapy. The SWE-NEO study aims to compare these two regimens, where the PD-1/CTLA-4 combination is potentially more effective, but also associated with more side effects.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Disease stage
Required: Stage III
Performance status
WHO 0–1
Prior therapy
Cannot have received: checkpoint inhibitor
No prior immunotherapy targeting CTLA-4, PD-1 or PD-L1.
Cannot have received: BRAF inhibitor
No prior targeted therapy targeting BRAF and/or MEK.
Cannot have received: MEK inhibitor
No prior targeted therapy targeting BRAF and/or MEK.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify